Evidence map›Paper›PMID 42675490›Full record

ReviewJournal of translational medicine2026

Resetting the immune setpoint of cold tumors through a ferroptosis-cGAS-STING amplification circuit.

Yi Wang, Xinru Li, Yuan Liang, Yawen Li, Yixin Zhao, Pengna Guo, Yuguang Zhao

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yi WangCancer Center, The First Hospital of Jilin University, No. 71 Xinmin Street, Chaoyang District Changchun, Changchun, Jilin, 130021, China.
Xinru LiCancer Center, The First Hospital of Jilin University, No. 71 Xinmin Street, Chaoyang District Changchun, Changchun, Jilin, 130021, China.
Yuan LiangCancer Center, The First Hospital of Jilin University, No. 71 Xinmin Street, Chaoyang District Changchun, Changchun, Jilin, 130021, China.
Yawen LiCancer Center, The First Hospital of Jilin University, No. 71 Xinmin Street, Chaoyang District Changchun, Changchun, Jilin, 130021, China.
Yixin ZhaoCancer Center, The First Hospital of Jilin University, No. 71 Xinmin Street, Chaoyang District Changchun, Changchun, Jilin, 130021, China.
Pengna GuoCancer Center, The First Hospital of Jilin University, No. 71 Xinmin Street, Chaoyang District Changchun, Changchun, Jilin, 130021, China.
Yuguang ZhaoCancer Center, The First Hospital of Jilin University, No. 71 Xinmin Street, Chaoyang District Changchun, Changchun, Jilin, 130021, China. zhaoyuguang@jlu.edu.cn.ORCID 0000-0002-4430-7798

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cold tumors remain a major challenge in cancer immunotherapy because of insufficient immune cell infiltration and limited inflammatory signaling, resulting in poor responses to immune checkpoint inhibitors. However, accumulating evidence suggests that many cold tumors are not completely immunologically inert but instead persist in a low-level immune state that fails to sustain effective immune amplification. Based on this perspective, we propose that cold tumors can be more appropriately understood as a threshold-constrained immune state, in which antitumor immune responses have been initiated but remain unable to surpass the immune activation threshold required to establish sustained immune amplification. Within this conceptual framework, we further propose a hierarchical model of immune dysfunction consisting of priming failure, trafficking failure, and penetration failure to explain the systemic mechanisms underlying immune resistance in cold tumors. Building upon this framework, we introduce the Ferroptosis-cGAS-STING amplification circuit as a conceptual model for driving immune state transition. In this model, ferroptosis activates the cGAS-STING-type I interferon axis through the release of tumor antigens and DNA-derived danger signals, whereas STING signaling, in turn, enhances cellular susceptibility to ferroptosis, thereby forming a transient amplification module constrained by temporal and metabolic conditions. This amplification module may enable subthreshold immune responses to overcome the immune activation threshold, thereby creating conditions for subsequent immune amplification while coordinately improving immune priming, immune cell recruitment, and tumor penetration, ultimately alleviating hierarchical immune barriers. Furthermore, we define the functional reprogramming of the tumor-immune system driven by crossing the immune activation threshold as immune setpoint resetting. We also discuss the key regulatory determinants and biological boundaries of this conceptual framework, including the temporal window of amplification, signal intensity, spatial constraints, and functional heterogeneity across different tumor contexts, together with its current limitations and future research directions. Overall, this review establishes a unified conceptual framework linking ferroptosis, innate immune activation, and immune remodeling in cold tumors, providing a systems-level perspective for understanding immune state transition and a theoretical foundation for designing immune interventions based on threshold crossing.

Indexed as

FerroptosisMembrane ProteinsNeoplasmsNucleotidyltransferasesAnimalscGAS-STING Signaling PathwayCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseHumansImmunotherapyModels, BiologicalSignal TransductionSTING ProteincGAS protein, humanCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseMembrane ProteinsNucleotidyltransferasesSTING1 protein, humanSTING ProteincGAS-STING pathwayCold tumorsFerroptosisImmunotherapyTumor immune microenvironment

Identifiers

PMID42675490
PMCPMC13531847

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.